Artificial intelligence for newborn metabolic screening
Part of Genetic & congenital clinical trials.
This study uses artificial intelligence (AI) to review newborn screening data for inherited metabolic diseases. It aims to improve early detection and help doctors identify at-risk babies sooner.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your baby had a routine newborn screening blood test for inherited metabolic disorders in the Zhejiang Provincial program between May 2025 and December 2027.
- The blood sample was collected when your baby was between 2 and 28 days old.
- Your baby's screening results and relevant health information are complete and available.
- You don't have incomplete, poor-quality, or duplicate screening samples.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial uses artificial intelligence to review newborn medical records, including scans and clinical notes, to help predict and improve health outcomes. Participation may help refine AI tools for neonatal care.
This study uses artificial intelligence to watch and analyze videos of newborns in the hospital nursery or NICU to help doctors spot neurological problems early. The goal is to see if this video AI tool can safely and accurately help care for newborns during their hospital stay.
This study is testing whether an artificial intelligence (AI) tool can help doctors diagnose rare diseases that have been hard to identify. If you join, the AI will review your medical information and previous test results to suggest possible diagnoses, which might speed up finding the right answer for you.
This study uses a simple blood spot and urine test to look for chemical signs of rare metabolic diseases. It aims to improve early detection and understanding of these conditions across all ages, including healthy individuals.
This study uses an artificial intelligence (AI) model to help doctors identify heart problems in unborn babies by analyzing fetal heart ultrasound images. It aims to improve early detection and diagnosis of congenital heart disease.
This study looks at children who may have genetic (inherited) or metabolic (body chemistry) problems, including newborn screening and episodes of trouble. The goal is to better understand these conditions and identify children who may benefit from further care.
Hear when a new Inherited Metabolic Disorders trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.